{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:48:23Z","timestamp":1791312503137,"version":"4.3.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.kint.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,9,18]],"date-time":"2016-09-18T14:00:52Z","timestamp":1474207252000},"page":"1115-1122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":226,"title":["Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease"],"prefix":"10.1016","volume":"90","author":[{"given":"Pablo E.","family":"Pergola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Maroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker H.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"117","key":"10.1016\/j.kint.2016.07.019_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ki.2010.188","article-title":"Anemia management in chronic kidney disease","author":"Fishbane","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib3","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.07.019_bib4","first-page":"11","article-title":"Cardio-renal anemia syndrome","volume":"12","author":"Efstratiadis","year":"2008","journal-title":"Hippokratia"},{"key":"10.1016\/j.kint.2016.07.019_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-14-2","article-title":"The development of anemia is associated to poor prognosis in NKF\/KDOQI stage 3 chronic kidney disease","volume":"14","author":"Portoles","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib7","first-page":"241","article-title":"Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature","volume":"13","author":"van Nooten","year":"2010","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.kint.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"h2258","DOI":"10.1136\/bmj.h2258","article-title":"Management of anaemia in chronic kidney disease: summary of updated NICE guidance","volume":"350","author":"Padhi","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.07.019_bib11","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.07.019_bib12","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"12","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000330693","article-title":"Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients","volume":"34","author":"Weinhandl","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","article-title":"Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients","volume":"53","author":"Kalantar-Zadeh","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.07.019_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1093\/ndt\/gfs123","article-title":"Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR","volume":"27","author":"Inrig","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients","volume":"37","author":"Okazaki","year":"2014","journal-title":"Blood Purif"},{"key":"10.1016\/j.kint.2016.07.019_bib18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","article-title":"Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients","volume":"3","author":"Kilpatrick","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2014.179","article-title":"ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target","volume":"86","author":"Hung","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.07.019_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2146\/ajhp110231","article-title":"Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease","volume":"69","author":"Liles","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.kint.2016.07.019_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.kint.2016.07.019_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11906-016-0629-6","article-title":"Hypoxia-inducible factor stabilizers: a new avenue for reducing BP while helping hemoglobin?","volume":"18","author":"Yousaf","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2016.07.019_bib23","first-page":"435A","article-title":"AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia","volume":"22","author":"Hartman","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib24","first-page":"435A","article-title":"AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults","volume":"22","author":"Shalwitz","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMp0912328","article-title":"Erythropoiesis-stimulating agents\u2014time for a reevaluation","volume":"362","author":"Unger","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.07.019_bib26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.07.019_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ackd.2008.12.007","article-title":"What is so bad about a hemoglobin level of 12 to 13 g\/dL for chronic kidney disease patients anyway?","volume":"16","author":"Besarab","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2016.07.019_bib28","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1101\/gad.250167.114","article-title":"Human high-altitude adaptation: forward genetics meets the HIF pathway","volume":"28","author":"Bigham","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.kint.2016.07.019_bib29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.07.019_bib30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2215\/CJN.04920908","article-title":"Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality","volume":"4","author":"Boudville","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.07.019_bib31","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.07.019_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.07.019_bib33","doi-asserted-by":"crossref","first-page":"19533","DOI":"10.1074\/jbc.M111.238667","article-title":"Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis","volume":"286","author":"Anderson","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.07.019_bib34","doi-asserted-by":"crossref","first-page":"E4922","DOI":"10.1073\/pnas.1314197110","article-title":"Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia","volume":"110","author":"Anderson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.07.019_bib35","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.07.019_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2016.07.019_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-05-647404","article-title":"Suppression of plasma hepcidin by venesection during steady-state hypoxia","volume":"127","author":"Talbot","year":"2016","journal-title":"Blood"},{"issue":"3 Suppl 1","key":"10.1016\/j.kint.2016.07.019_bib38","article-title":"US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.07.019_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1101\/sqb.2011.76.010678","article-title":"Regulation of metabolism by hypoxia-inducible factor 1","volume":"76","author":"Semenza","year":"2011","journal-title":"Cold Spring Harbor Symp Quant Biol"},{"key":"10.1016\/j.kint.2016.07.019_bib40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.yexcr.2012.02.026","article-title":"Renal cancer: oxygen meets metabolism","volume":"318","author":"Haase","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.kint.2016.07.019_bib41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tem.2012.05.003","article-title":"Novel links between HIFs, type 2 diabetes, and metabolic syndrome","volume":"23","author":"Girgis","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.kint.2016.07.019_bib42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.07.019_bib43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.kint.2016.07.019_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2016.07.019_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","article-title":"Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology","volume":"9","author":"Semenza","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.kint.2016.07.019_bib46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/MCB.01055-15","article-title":"The endothelial prolyl-4-hydroxylase domain 2\/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice","volume":"36","author":"Kapitsinou","year":"2016","journal-title":"Mol Cell Biol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381630357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381630357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T18:07:07Z","timestamp":1568398027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381630357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S008525381630357X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.07.019","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}